Literature DB >> 31265606

Erratum: Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment: Erratum.

.   

Abstract

[This corrects the article DOI: 10.1097/MD.0000000000002016.].

Entities:  

Year:  2016        PMID: 31265606      PMCID: PMC5017253          DOI: 10.1097/01.md.0000479949.09661.21

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


In the article “Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment”,[1] which appeared in Volume 94, Issue 45 of Medicine, funding information was originally omitted. The article has since been corrected online.
  1 in total

1.  Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.

Authors:  R A Werner; J S Schmid; D O Muegge; K Lückerath; T Higuchi; H Hänscheid; I Grelle; C Reiners; K Herrmann; A K Buck; C Lapa
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.